A
1 Byte
Oligonucleotide Synthesis Market Trends Analysis Report By Deployment Mode, End-Use, Application And Growth Forecasts, 2035
Oligonucleotide Synthesis Market Overview
The global oligonucleotide synthesis market size is estimated to be worth $ 4.8 billion in 2024 and is expected to grow at compounded annual growth rate (CAGR) of 9.9% during the forecast period 2024-2035. There has been a significant rise in the investments made by big pharma players in this domain, over the past few years.
Oligonucleotide Synthesis Market Segmentation
Oligonucleotide Synthesis Market focuses on Application Area (Research and Diagnostics, and Therapeutics), Type of Product Synthesized (Active Pharmaceutical Ingredients and Finished Dosage Forms), Type of Oligonucleotide Synthesized (Antisense, DNA, siRNA and Other Oligonucleotides), Scale of Operation (Clinical and Commercial), Therapeutic Area (Cardiovascular Disorders, Genetic Disorders, Liver Disorders, Rare Diseases, and Other Disorders), End-Users (Pharmaceutical / Biopharmaceutical Companies, Academic and Research Institutes, and Hospitals), Company Size (Small, Mid-sized, and Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World).
Oligonucleotide Synthesis Market Key Companies
Examples of key oligonucleotide synthesis companies include Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Merck, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, Thermo Fisher Scientific, TriLink Biotechnologies. These players have undertaken a number of initiatives in order to expand their respective product portfolios and augment their capabilities.
It is worth highlighting that 19% of the initiatives were reported in 2023; of these, majority 49% of the partnership initiatives were instances of mergers and acquisitions.Further, 39% of the initiatives undertaken by big pharma players are focused on manufacturing of RNAi oligonucleotides, followed by 29% on antisense oligonucleotides. Notable examples of companies engaged in the manufacturing of RNAi oligonucleotides include (in alphabetical order) Bristol Myers Squibb, Novartis, Novo Nordisk and Roche. Further, it is worth highlighting that Roche has invested more than USD 750 million for the development and commercialization of RNAi oligonucleotides in the given time period.
Owing to several factors, including globalization and introduction of political and regulatory
reforms, advanced contract manufacturing services for oligonucleotides are no longer confined to the developed geographies alone. Currently, several players in emerging geographies, such as those based in China, India, Asia-Pacific and Latin America, offer high quality contract manufacturing services for oligonucleotides, along with providing lucrative cost benefits. Maximum oligonucleotide synthesis capacity is installed in the facilities located in North America this can be attributed to the inherent technological advancements and well-established regulatory landscape of this region.
This is followed by oligonucleotide synthesis capacity installed in facilities located in Asia-Pacific and rest of the world owing to the low cost of labor and other resources, players based in this region have managed to establish production facilities with high capacity. The global, installed oligonucleotide synthesis capacity is spread across various geographies and more than 75% of the total capacity is installed at the facilities owned by large and very large players.
Browse Complete Report at: https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html
Browse More Related Promotions:
https://www.coffeesix-store.com/board/board_topic/7560063/6198408.htm
https://www.ownedcore.com/forums/members/1495457-rupali14mehta.html
https://forumreklamowe.com/Thread-Research-Reports
https://blogulr.com/rupali14mehta/oligonucleotide-synthesis-market-size-share-analysis-2035-112289
https://yhg.copiny.com/idea/details/id/180441
https://theduran.com/?p=153433&preview=true
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.
All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.
Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/
Please
register
or
sign in
to comment